Radiolabeled glucose derivatives for tumor imaging using SPECT and PET

Current Medicinal Chemistry

Volumn 21, Issue 1, 2014, Pages 24-34

  Liu, T ^a   Zhang, J ^a   Wang, X ^a   Yang, J ^b   Tang, Z ^a   Lu, J ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Glucose derivatives; PET; Radiotracers; SPECT; Tumor imaging

Indexed keywords

1 (2 DEOXY 2 FLUORO B DEXTRO GLUCOPYRANOSYL) 2 NITROIMIDAZOLE F 18; 1 THIO BETA DEXTRO GLUCOSE TC 99M; 2 (4 ISOTHIOCYANATOBENZYL) 1,4,7,10 TETRAAZACYCLO DODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO GLUCOSE GA 68; 2 (4 ISOTHIOCYANATOBENZYL) 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEOXYGLUCOSONE IN 111; DEOXYGLUCOSE DITHIOCARBAMIC ACID TC 99M; DIETHYLENETRIAMINEPENTAACETIC ACID DEOXYGLUCOSE TC 99M; DIGLUCOSEDIETHYLENETRIAMINE TC 99M; ETHYLENEDICYSTEINE DEOXYGLUCOSE TC 99M; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUORODEOXYGLUCOSE FOLIC ACID F 18; GLUCARATE TC 99M; GLUCOSE DERIVATIVE; MERCAPTOACETYLGLYCYLGLYCYLGLYCINE DEOXYGLUCOSE TC 99M; MERCAPTOACETYLGLYCYLGLYCYLGLYCINE GLUCOSE TC 99M; TECHNETIUM 99M; TRACER; UNCLASSIFIED DRUG;

ARTICLE; BREAST TUMOR; DRUG UPTAKE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; ISOTOPE LABELING; MELANOMA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPOROMANDIBULAR JOINT; TUMOR DIAGNOSIS;

ANIMALS; HUMANS; ISOTOPE LABELING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84889591164     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990254     Document Type: Article

References (101)

1. Muller, C.; Schibli, R. Single photon emission computed tomography tracer. Recent results in cancer research. Fortschritte der Krebsforschung. Recent Results Cancer Res., 2013, 187, 65-105.
2. Yang, D. J.; Kim, C. G.; Schechter, N. R.; Azhdarinia, A.; Yu, D. F.; Oh, C. S.; Bryant, J. L.; Won, J.J.; Kim, E. E.; Podoloff, D.A. Imaging with 99mTc ECDG Targeted at the Multifunctional Glucose Transport System Feasibility Study with Rodents. Radiology, 2003, 226(2), 465-473. (Pubitemid 36313436)
3. Schechter, N. R.; Erwin, W. D.; Yang, D. J.; Kim, E. E.; Munden, R. F.; Forster, K.; Taing, L. C.; Cox, J. D.; Macapinlac, H.A.; Podoloff, D.A. Radiation dosimetry and biodistribution of 99mTcethylene dicysteine-deoxyglucose in patients with non-small-cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36(10), 1583-1591.
4. Yang, D.; Yukihiro, M.; Yu, D.F.; Ito, M.; Oh, C.S.; Kohanim, S.; Azhdarinia, A.; Kim, C.G.; Bryant, J.; Kim, E. E.; Podoloff, D. A. Assessment of therapeutic tumor response using 99mTcethylenedicysteine-glucosamine. Cancer Biother. Radio., 2004, 19(4), 443-456. (Pubitemid 39281335)
5. Chen, Y.; Huang, Z.W.; He, L.; Zheng, S.L.; Li, J.L.; Qin, D.L. Synthesis and evaluation of a technetium-99m-labeled diethylenetriaminepentaacetate- deoxyglucose complex ([99mTc]-DTPA-DG) as a potential imaging modality for tumors. Appl. Radiat. Isot., 2006, 64(3), 342-347. (Pubitemid 41803063)
6. Chen, Y.; Xiong, Q.; Yang, X.; Huang, Z.; Zhao, Y.; He, L. Noninvasive scintigraphic detection of tumor with 99mTc-DTPAdeoxyglucose: an experimental study. Cancer Biother. Radio., 2007, 22(3), 403-405. (Pubitemid 47067898)
7. Liang, J.; Chen, Y.; Huang, Z.; Zhao, Y.; He, L. Early chemotherapy response evaluation in tumors by 99mTc-DTPA-DG. Cancer Biother. Radio., 2008, 23(3), 363-370. (Pubitemid 351931456)
8. Xiong, Q.; Chen, Y. Deoxyglucose compounds labeled with isotopes different from 18-fluoride: is there a future in clinical practice. Cancer Biother. Radio., 2008, 23(3), 376-381. (Pubitemid 351931454)
9. Sun, Y.; Chen, Y. Cancer drug development using glucose metabolism radiopharmaceuticals. Curr. Pharm. Design, 2009, 15, 983-987.
10. Zhang, J.; Ren, J.; Lin, X.; Wang, X. Synthesis and biological evaluation of a novel 99mTc nitrido radiopharmaceutical with deoxyglucose dithiocarbamate, showing tumor uptake. Bioorg. Med. Chem. Lett., 2009, 19(10), 2752-2754.
11. Lin, X.; Jin, Z.; Ren, J.; Pang, Y.; Zhang, W.; Huo, J.; Wang, X.; Zhang, J.; Zhang, Y. Synthesis and biodistribution of a new 99mTcoxo complex with deoxyglucose dithiocarbamate for tumor imaging. Chem. Biol. Drug Des., 2012, 79(3), 239-245.
12. Ballinger, J.R.; Hsue, V.; Rauth, A.M. Accumulation of technetium-99m glucarate: in vitro cell cultures and in vivo tumour models. Nucl. Med. Commun., 2003, 24, 597-606.
13. Liu, Z.; Stevenson, G. D.; Barrett, H. H.; Kastis, G. A.; Bettan, M.; Furenlid, L. R.; Wilson, D. W.; Woolfenden, J. M.; Pak, K. Y. 99mTc glucarate high-resolution imaging of drug sensitive and drug resistant human breast cancer xenografts in SCID mice. Nucl. Med. Commun., 2004, 25(7), 711-720. (Pubitemid 38901689)
14. Perek, N.; Sabido, O.; Jeune, N. L.; Prevot, N.; Vergnon, J.M.; Clotagatide, A.; Dubois, F. Could 99mTc-glucarate be used to evaluate tumor necrosis? Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 1290-1298.
15. Gambini, J. P.; Nuñez, M.; Cabral, P.; Lafferranderie, M.; Noble, J.; Corchs, E.; D'Albora, R.; Savio, E.; Delgado, L.; Alonso, O. Evaluation of patients with head and neck cancer by means of 99mTc-glucarate. J. Nucl. Med. Technol., 2009, 37, 229-232.
16. Gambini, J. P.; Cabral, P.; Alonso, O.; Savio, E.; Figueroa, S. D.; Zhang, X.; Ma, L.; Deutscher, S. L.; Quinn, T. P. Evaluation of 99mTc-glucarate as a breast cancer imaging agent in a xenograft animal model. Nucl. Med. Biol., 2011, 38(2), 255-260.
17. Cheng, D.F.; Rusckowski, M.; Wang, Y.Z.; Liu, Y.X.; Liu, G.Z.; Liu, X.R.; Hnatowich, D. A brief evaluation of tumor imaging in mice with 99mTc-glucarate including a comparison with 18F-FDG. Curr. Radiopharm., 2011,4, 5-9.
18. Isnardi, V.; Clotagatide, A.; Bruel, S.; Perek, N. Is 99mTc-glucarate uptake mediated by fructose transporter GLUT-5? Nucl. Med. Biol., 2012, 39, 1226-1231.
19. Chen, X.; Li, L.; Liu, F. and Liu, B. Synthesis and biological evaluation of technetium-99m-labeled deoxyglucose derivatives as imaging agents for tumor. Bioorg. Med. Chem. Lett., 2006, 16(21), 5503-5506. (Pubitemid 44415465)
20. De Barros, A. L.; Cardoso, V. N.; Mota, L.; Leite, E. A.; Oliveira, M. C.; Alves, R. J. Synthesis and biological evaluation of technetium-labeled D-glucose-MAG3 derivative as agent for tumor diagnosis. Bioorg. Med. Chem. Lett., 2009, 19(9), 2497-2499.
21. De Barros, A. L.; Cardoso, V. N.; Mota, L.; Alves, R. J. Synthesis and biodistribution studies of carbohydrate derivatives radiolabeled with technetium-99m. Bioorg. Med. Chem. Lett., 2010, 20(1), 315-317.
22. De Barros, A. L.; Cardoso, V. N.; Mota, L.; Leite, E. A.; De Oliveira, M. C.; Alves, R. J. A novel D-glucose derivative radiolabeled with technetium-99m: synthesis, biodistribution studies and scintigraphic images in an experimental model of Ehrlich tumor. Bioorg. Med. Chem. Lett., 2010, 20(8), 2478-2480.
23. Ferreira, C. L.; Marques, F. L.; Okamoto, M. R.; Otake, A. H.; Sugai, Y.; Mikata, Y.; Storr, T.; Bowen, M.;Yano, S.; Adam, M. J.; Chammas, R.; Orvig, C. Cationic technetium and rhenium complexes with pendant carbohydrates. Appl. Radiat. Isot., 2010, 68(6), 1087-1093.
24. Jun Oh, S.; Ryu, J. S.; Yoon, E. J.; Bae, M. S.; Choi, S. J.; Park, K. B.; Moon, D. H. 99mTc-labeled 1-thio-beta-D-glucose as a new tumor-seeking agent: synthesis and tumor cell uptake assay. Appl. Radiat. Isot., 2006, 64(2), 207-215. (Pubitemid 41688431)
25. Castelli, R.; Fernández, M.; Porcal, W.; Gambini, J.; Alonso, O.; Chabalgoity, A.; Moreno, M.; Cabral, P. Preparation and primary bioevaluation of 99mTc-labeled-1-thio-D-glucose as melanoma targeting agent. Curr. Radiopharm., 2011, 4(4), 355-360.
26. Brasileiro, C. B.; Pacheco, C. M.; Queiroz-Junior, C. M.; De Lima, C. F.; Da Silva, J. B.; De Campos, T. P. 99mTc-labeled-1-thio-betad-glucose as a new tool to temporomandibular joint inflammatory disorders diagnosis. Appl. Radiat. Isot., 2010, 68(12), 2261-2267.
27. Petrig, J.; Schibli, R.; Dumas, C. C.; Alberto, R.; Schubiger, P. A. Derivatization of glucose and 2-deoxyglucose for transition metal complexation substitution reactions with organometallic 99mTc and Re precursors and fundamental NMR investigations. Chem. Eur. J., 2001, 7(9), 1868-1873. (Pubitemid 32433651)
28. Dapueto, R.; Castelli, R.; Fernandez, M.; Chabalgoity, J. A.; Moreno, M.; Gambini, J. P.; Cabral, P.; Porcal, W. Biological evaluation of glucose and deoxyglucose derivatives radiolabeled with [99mTc(CO)3(H2O)3]+ core as potential melanoma imaging agents. Bioorg. Med. Chem. Lett., 2011, 21(23), 7102-7106.
29. Fernández, S.; Crócamo, N.; Incerti, M.; Giglio, J.; Se, L.; Rey, A. Preparation and preliminary bioevaluation of a 99mTc(CO)3-glucose derivative prepared by a click chemistry route. J. Labelled Compd. Rad., 2012, 55(7), 274-280.
30. Lee, S.J.; Oh, S.J.; Kim, J.Y.; Ryu, J.S.; Kim, S.Y.; Moon, D.H. Synthesis and in vitro evaluation of 99mTc-diglucosediethylenetriamine (DGTA) as a potential tumor imaging agent. Bull. Korean Chem. Soc., 2011, 32(7), 2410-2412.
31. Alberto, R.; Ortner, K.; Wheatley, N.; Schibli, R.; Schubiger, P.A. Synthesis and properties of boranocarbonate: a convenient in situ CO for the aqueous preparation of 99mTc(OH2)3(CO)3+. J. Am. Chem. Soc., 2001, 123, 3135-3136.
32. Storr, T.; Sugai, Y.; Barta, C. A.; Mikata, Y.; Adam, M. J.; Yano, S.; Orvig, C. Carbohydrate-appended 2,2'-dipicolylamine metal complexes as potential imaging agents. Inorg. Chem., 2005, 44(8), 2698-2075.
33. Storr, T.; Fisher, C. L.; Mikata, Y.; Yano, S.; Adam, M. J.; Orvig, C. A glucosamine-dipicolylamine conjugate of 99mTc(I) and 186Re(I) for use in imaging and therapy. Dalton Trans., 2005, 4, 654-655. (Pubitemid 40308516)
34. Bowen, M.L.; Orvig, C. Technetium-99m carbohydrate conjugates as potential agents in molecular imaging. Chem. Commun., 2008, 4, 5077-5091.
35. Benoist, E.; Coulais, Y.; Almant, M.; Kovensky, J.; Moreau, V.; Lesur, D.; Artigau, M.; Picard, C.; Galaup, C.; Gouin, S. G. A click procedure with heterogeneous copper to tether technetium-99m chelating agents and rhenium complexes. Evaluation of the chelating properties and biodistribution of the new radiolabelled glucose conjugates. Carbohyd. Res., 2011, 346(1), 26-34.
36. Ferreira, C. L.; Bayly, S. R.; Green, D. E.; Storr, T.; Barta, C. A.; Steele, J.; Adam, M. J.; Orvig, C. Carbohydrate-appended 3-hydroxy-4-pyridinone complexes of the M(CO)3+ Core (M=Re, 99mTc, 186Re). Bioconjugate Chem., 2006, 17(5), 1321-1329.
37. Bayly, S. R.; Fisher, C. L.; Storr, T.; Adam, M. J.; Orvig, C. Carbohydrate conjugates for molecular imaging and radiotherapy 99mTc(I) and 186Re(I) tricarbonyl complexes of N-(2'-Hydroxy benzyl)-2-amino-2-deoxy-D- glucose. Bioconjugate Chem., 2004, 15(4), 923-926. (Pubitemid 38986970)
38. Dumas, C.; Petrig, J.; Schibli, R.; Stahel, J.; Schubiger, P. A.; Spadola, L.; Scapozza, L.; Mertens, J. Functionalization of glucose for the labeling with 99mTc-tricarbonyl. J. Labelled Compd. Rad., 2001, 44(1), 57-59.
39. Schibli, R.; Dumas, C.; Petrig, J.; Spadola, L.; Scapozza, L.; Garcia-Garayoa, E.; Schubige, P. A. Synthesis and in vitro characterization of organometallic rhenium and technetium glucose complexes against glut 1 and hexokinase. Bioconjugate Chem., 2005, 16(1), 105-121.
40. Ferreira, C. L.; Ewart, C. B.;Bayly, S. R.;Patrick, B. O.;Steele, J.;Adam, M. J.; Orvig, C. Glucosamine Conjugates of Tricarbonylcyclopentadienyl Rhenium(I) and Technetium. Inorg. Chem., 2006, 45(17), 6979-6987.
41. Storr, T.; Obata, M.; Fisher, C. L.; Bayly, S. R.; Green, D. E.; Brudzinska, I.; Mikata, Y.; Patrick, B. O.; Adam, M. J.; Yano, S.; Orvig, C. Novel carbohydrate-appended metal complexes for potential use in molecular imaging. Chem. Eur. J., 2004, 11(1), 195-203.
42. Gottschaldt, M.; Koth, D.; Muller, D.; Klette, I.; Rau, S.; Gorls, H.; Schafer, B.; Baum, R. P.; Yano, S. Synthesis and structure of novel sugar-substituted bipyridine complexes of rhenium and 99mtechnetium. Chem. Eur. J., 2007, 13(36), 10273-10280.
43. Yang, Z.; Zhu, H.; Lin, X.F. Synthesis and evaluation of 111Inlabeled D-glucose as a potential SPECT imaging agent. J. Radioanal. Nucl. Chem., 2012, 295(2), 1371-1375.
44. Rohren, E. M.; Turkington, T. G.; Coleman, R. E. Clinical Applications of PET in Oncology. Radiology, 2004, 231(2), 305-332. (Pubitemid 38552885)
45. Imam, S. K. Molecular nuclear imaging the radiopharmaceuticals. Cancer Biother. Radio., 2005, 20(2), 163-172.
46. Som, P.; Atkins, H.L.; Bandoypadhyay, D.; Fowler, J. S.; Macgregor, R. R.; Matsui, K.; Oster, Z.H.; Sacker, D. F.; Shiue, C. Y.; Turner, H.; Wan, C.N.; Wolf, A. P.; Zabinski, S. V. A fluorinated glucose analog, 2-fluoro-2-deoxy-D- glucose (F-18) nontoxic tracer for rapid tumor detection. J. Nucl. Med., 1980, 21(7), 670-675. (Pubitemid 10034639)
47. Schmid, R.; Hautmann, H.; Poellinger, B.; Kellner, W.; Moisseev, A.; Brinkbaeumer, K.; Weiss, M.; Hahn, K.; Dresel, S. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET). Nucl. Med. Commun., 2003, 24(1), 37-45.
48. Hicks, R. J.; Kalff, V.; Macmanus, M. P.; Ware, R. E.; Mckenzie, A. F.; Matthews, J. P.; Ball, D. L. The utility of 18F-FDG PET for suspected recurrent nonsmall cell lung cancer after potentially curative therapy impact on management and prognostic stratification. J. Nucl. Med., 2001, 42(11), 1605-1613. (Pubitemid 33131318)
49. Hicks, R. J. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J. Nucl. Med., 2009, 50(1), 31S-42S.
50. Verboom, P.; Van Tinteren, H.; Hoekstra, O. S.; Smit, E. F.; Van Den Bergh, J. H.; Schreurs, A. J.; Stallaert, R. A.; Van Velthoven, P. C.; Comans, E. F.; Diepenhorst, F. W.; Van Mourik, J. C.; Postmus, P. E.; Boers, M.; Grijseels, E. W.; Teule, G. J.; Uyl-De Groot, C. A.; Group, P. S. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur. J. Nucl. Med. Mol. Imaging, 2003, 30(11), 1444-1449. (Pubitemid 37356109)
51. Eschmann, S. M.; Friedel, G.; Paulsen, F.; Reimold, M.; Hehr, T.; Budach, W.; Langen, H. J.; Bares, R. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34(4), 463-471. (Pubitemid 46426996)
52. Hellwig, D.; Groschel, A.; Graeter, T. P.; Hellwig, A. P.; Nestle, U.; Schafers, H. J.; Sybrecht, G. W.; Kirsch, C. M. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. Eur. J. Nucl. Med. Mol. Imaging, 2006, 33(1), 13-21. (Pubitemid 41785304)
53. Tulchinsky, M.; Coquia, S. and Wagner, H. J. Small bowel metastasis from lung cancer detected on FDG PET/CT. Clin. Nucl. Med., 2009, 34(7), 446-448.
54. Yamamoto, Y.; Kameyama, R.; Murota, M.; Bandoh, S.; Ishii, T. and Nishiyama, Y. Early assessment of therapeutic response using FDG PET in small cell lung cancer. Mol. Imaging Biol., 2009, 11(6), 467-472.
55. De Geus-Oei, L. F.; Van Der Heijden, H. F.; Visser, E. P.; Hermsen, R.; Van Hoorn, B. A.; Timmer-Bonte, J. N.; Willemsen, A. T.; Pruim, J.; Corstens, F. H.; Krabbe, P. F.; Oyen, W. J. Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J. Nucl. Med., 2007, 48(10), 1592-1598. (Pubitemid 47572705)
56. Basely, M. J.; Bernard, P.; Gisserot, O.; Maszelin, P.; Bussy, E.; Jaureguiberry, J.P. Umbilical metastasis from breast cancer detected by FDG PET. Clin. Nucl. Med., 2009, 34(5), 292-293.
57. Duch, J.; Fuster, D.; Munoz, M.; Fernández, P.L.; Paredes, P.; Fontanillas, M.; Guzmán, F.; Rubí, S.; Lomeña, F.J.; Pons, F. [18F]FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36(10), 1551-1557.
58. Aukema, T. S.; Straver, M. E.; Olmos, R. A. V.; Vogel, W. V. A different role for FDG PET/CT in axillary lymph node staging in breast cancer. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36(11), 1896-1897.
59. Belohlavek, O. What is the role of FDG-PET in the initial staging of breast cancer? Eur. J. Nucl. Med. Mol. Imaging, 2008, 35(3), 472-474.
60. Cermik, T. F.; Mavi, A.; Basu, S.; Alavi, A. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35(3), 475-483. (Pubitemid 351661670)
61. Crippa, F.; Gerali, A.; Alessi, A.; Agresti, R.; Bombardieri, E. FDG-PET for axillary lymph node staging in primary breast cancer. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31(1), S97-S102. (Pubitemid 38833038)
62. Kumar, A.; Kumar, R.;Seenu, V.; Gupta, S. D.; Chawla, M.; Malhotra, A.; Mehta, S. N. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur. Radiol., 2009, 19(6), 1347-1357.
63. Kitajima, K.; Murakami, K.; Yamasaki, E.; Domeki, Y.; Tsubaki, M.; Sunagawa, M.; Kaji, Y.; Suganuma, N.; Sugimura, K. Performance of integrated FDG PET/contrast-enhanced CT in the diagnosis of recurrent colorectal cancer: Comparison with integrated FDG PET/non-contrast-enhanced CT and enhanced CT. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36(9), 1388-1396.
64. Votrubova, J.; Belohlavek, O.; Jaruskova, M.; Oliverius, M.; Lohynska, R.; Trskova, K.; Sedlackova, E.; Lipska, L.; Stahalova, V. The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur. J. Nucl. Med. Mol. Imaging, 2006, 33(7), 779-784. (Pubitemid 43979685)
65. Kazama, T.; Faria, S.C.; Varavithya, V.; Phongkitkarun, S.; Hisao Ito, M.; Macapinlac, H. A. FDG PET in the evaluation of treatment for lymphoma clinical usefulness and pitfalls. Radiographics, 2005, 25(1), 191-207. (Pubitemid 40186951)
66. Kumar, R.; Xiu, Y.; Mavi, A.; El-Haddad, G.; Zhuang, H.; Alavi, A. FDG-PET imaging in primary bilateral adrenal lymphoma a case report and review of the literature. Clin. Nucl. Med., 2005, 30(4), 222-230. (Pubitemid 40396815)
67. Branstetter IV, B. F.; Blodgett, T. M.; Zimmer, L. A.; Snyderman, C. H.; Johnson, J. T.; Raman, S.; Meltzer, C. C. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology, 2005, 235(2), 580-586. (Pubitemid 40571100)
68. Nguyen, B. D.; Ram, P. C.; Roarke, M. C. Endotracheal metastasis from squamous cell cancer of the head and neck PET/CT imaging. Clin. Nucl. Med., 2008, 33(5), 340-341. (Pubitemid 351589528)
69. Guo, H.; Zhu, H.; Xi, Y.; Zhang, B.; Li, L.; Huang, Y.; Zhang, J.; Fu, Z.; Yang, G.; Yuan, S.; Yu, J. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus. J. Nucl. Med., 2007, 48(8), 1251-1258. (Pubitemid 47242789)
70. Krause, B.J.; Herrmann, K.; Wieder, H.; zum Buschenfelde, C.M. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer. J. Nucl. Med., 2009, 50(1), 89S-96S.
71. Strobel, K.; Dummer, R.; Husarik, D.B.; Lago, M. P. R.; Hany, T. F.; Steinert, H. C. High-risk melanoma accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology, 2007, 244(2), 566-574. (Pubitemid 47080890)
72. Jimenez-Requena, F.; Delgado-Bolton, R. C.; Fernandez-Perez, C.; Gambhir, S. S.; Schwimmer, J.; Perez-Vazquez, J. M.; Carreras-Delgado, J. L. Meta-analysis of the performance of 18F-FDG PET in cutaneous melanoma. Eur. J. Nucl. Med. Mol. Imaging, 2010, 37(2), 284-300.
73. Crippa, F.; Leutner, M.; Belli, F.; Gallino, F.; Greco, M.; Pilotti, S.; Cascinelli, N.; Bombarclieri, E. Which kinds of lymph node metastases can FDG PET detect? a clinical study in melanoma. J. Nucl. Med., 2000, 41(9), 1491-1494.
74. Strobel, K.; Heinrich, S.; Bhure, U.; Soyka, J.; Veit-Haibach, P.; Pestalozzi, B. C.; Clavien, P. A.; Hany, T. F. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J. Nucl. Med., 2008, 49(9), 1408-1413.
75. Nishivama, Y.; Yamamoto, Y.; Yokoe, K.; Monden, T.; Sasakawa, Y.; Tsutsui, K.; Satoh, K.; Ohkawa, M. Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer. Ann. Nucl. Med., 2005, 19(6), 491-497. (Pubitemid 41531270)
76. Higashi, T.; Saoa, T.; Nakamoto, Y.; Ishimori, T.; Fujimoto, K.; Doi, R.; Imamtjra, M.; Konishi, J. Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET). Ann. Nucl. Med., 2003, 17(4), 261-279.
77. Evans, K. D.; Tulloss, T. A.; Hall, N. 18F-FDG uptake in brown fat: potential for false positives. Radiol. Technol., 2007, 78(5), 361-366.
78. Okuma, T.; Matsuoka, T.; Okamura, T.; Wada, Y.; Yamamoto, A.; Oyama, Y.; Koyama, K.; Nakamura, K.; Watanabe, Y.; Inoue, Y. 18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits. J. Nucl. Med., 2006, 47(8), 1351-1358. (Pubitemid 47544891)
79. Zhu, A.; Lee, D.; Shim, H. Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin. Oncol., 2011, 38(1), 55-69.
80. Chierichetti, F.; Pizzolato, G. 18F-FDG-PET/CT. Q. J. Nucl. Med. Mol. Im., 2012, 56(2), 138-150.
81. Jaini, S.; Mbbs, M.; Dadachova, E. FDG for therapy of metabolically active tumors. Semin. Nucl. Med., 2012, 42(3), 185-189.
82. Waarde, A. V.; Cobben, D. C. P.; Suurmeijer, A. J. H.; Maas, B.; Vaalburg, W.; Vries, E. F. J. D.; Jager, P. L.; Hoekstra, H. J.; Elsinga, P. H. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J. Nucl. Med., 2004, 45(4), 695-700. (Pubitemid 47618601)
83. Ell, P. J.; Kayani, I.; Groves, A. M. 18F-fluorodeoxyglucose PET/CT in cancer imaging. Clin. Med., 2006, 6(3), 240-244. (Pubitemid 43954019)
84. Ido, T.; Wan, C.N.; Casella, V.; Fowler, J. S.; Wolf, A. P. Labeled 2-deoxy-d-glucose analogs. 18F-labeled 2-deoxy-2-fluoro-dglucose, 2-deoxy-2-fluoro-d-mannose and 4c-2-deoxy-2-fluoro-dglucose. J. Labelled Compd. Rad., 1978, 14(2), 175-183. (Pubitemid 8294308)
85. Gallagher, B. M.; Ansari, A.; Atkins, H.; Casella, V.; Christman, D. R.; Fowler, J. S.;Ido, T.; Macgregor, R.R.; Som, P.; Wan, C. N.; Wolf, A.P.; Kuhl, D.E.; Reivich, M. Radiopharmaceuticals XXVII. 18F-labeled 2-deoxy-2-fluoro-D- glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo tissue distribution and imaging studies in animals. J. Nucl. Med., 1977, 18(10), 990-996.
86. Reivich, M.; Kuhl, D.; Wolf, A.; Greenberg, J.; Phelps, M.; Ido, T.; Casella, V.; Fowler, J.; Hoffman, E.; Alavi, A.; Som, P.; Sokoloff, L. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ. Res., 1979, 44(1), 127-137. (Pubitemid 9089586)
87. Fischer, C. R.; Muller, C.; Reber, J.; Muller, A.; Kramer, S. D.; Ametamey, S. M.; Schibli, R. [18F]fluoro-deoxy-glucose Folate: A Novel PET Radiotracer with Improved in Vivo Properties for Folate Receptor Targeting. Bioconjugate Chem., 2012, 23(4), 805-813.
88. Fujiwara, T.; Kubota, K.; Sato, T.; Matsuzawa, T.; Tada, M.; Iwata, R.; Itoh, M.; Hatazawa, J.; Sato, K.; Fukuda, H.; Ido, T. N-F. Fluoroacetyl-D- glucosamine a potential agent for cancer diagnosis. J. Nucl. Med., 1990, 31(10), 1654-1658. (Pubitemid 20347048)
89. Wuest, M.; Kumar, P.; Wang, M.; Yang, J.; Jans, H. S.; Wiebe, L. I. In vitro and in vivo evaluation of [18F]F-GAZ, a novel oxygenmimetic azomycin-glucose conjugate, for imaging hypoxic tumor. Cancer Biother. Radio., 2012, 27(8), 473-480.
90. Patt, M.; Sorger, D.; Scheunemann, M.; Stocklin, G. Adduct of 2-[18F]FDG and 2-nitroimidazole as a putative radiotracer for the detection of hypoxia with PET: synthesis, in vitro-and in vivocharacterization. Appl. Radiat. Isot., 2002, 57, 705-712. (Pubitemid 35279160)
91. Kim, D. H.; Choe, Y. S.; Jung, K. H.; Lee, K. H.; Choi, J. Y.; Choi, Y.; Kim, B. T. A 18F-labeled glucose analog: synthesis using a click labeling method and in vitro evaluation. Arch. Pharm. Res., 2008, 31(5), 587-593.
92. Anderson, C. J.; Welch, M. J. Radiometal-labeled agents (nontechnetium) for diagnostic imaging. Chem. Rev., 1999, 99(9), 2219-2234.
93. Reichert, D. E.; Lewis, J. S.; Anderson, C. J. Metal complexes as diagnostic tools. Coord. Chem. Rev., 1999, 184, 3-66.
94. Wadas, T. J.; Wong, E. H.; Weisman, G. R.; Anderson, C. J. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr. Pharm. Design, 2007, 13(1), 3-16. (Pubitemid 46085298)
95. Shokeen, M.; Anderson, C. J. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc. Chem. Res., 2009, 42(7), 832-841.
96. Bayly, S. R.; King, R. C.; Honess, D. J.; Barnard, P. J.; Betts, H. M.; Holland, J. P.; Hueting, R.; Bonnitcha, P. D.; Dilworth, J. R.; Aigbirhio, F. I.; Christlieb, M. In vitro and in vivo evaluations of a hydrophilic 64Cu-bis(thiosemicarbazonato)-glucose conjugate for hypoxia imaging. J. Nucl. Med., 2008, 49(11), 1862-1868.
97. Roesch, F.; Riss, P. J. The renaissance of the 68Ge/68Ga radionuclide generator initiates new developments in 68Ga radiopharmaceutical chemistry. Curr. Top. Med. Chem., 2010, 10(16), 1633-1668.
98. Wadas, T. J.; Wong, E. H.; Weisman, G. R.; Anderson, C. J. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem. Rev., 2010, 110(5), 2858-2902.
99. Yang, Z.; Xiong, C.; Zhang, R.; Zhu, H.; Li, C. Synthesis and evaluation of 68Ga-labeled DOTA-2-deoxy-D-glucosamine as a potential radiotracer in PET imaging. Am. J. Nucl. Med. Mol. Imaging., 2012, 2(4), 499-507.
100. Yang, Z.; Zhu, H. Synthesis and evaluation of new nuclides Ga-68 labeled D-glucose for potential PET imaging agent. Acta Chim. Sinica, 2012, 70(9), 1066-1072.
101. Kurihara, H.; Honda, N.; Kono, Y.; Arai, Y. Radiolabelled agents for PET imaging of tumor hypoxia. Curr. Med. Chem., 2012, 19(20), 3282-32899